Coronavirus Infections
Conditions
Keywords
Coronavirus Infections, Health Personnel, Hydroxychloroquine, Pre-Exposure Prophylaxis, Antimalarials, Antirheumatic Agents, Ivermectin
Brief summary
We have to be aware of the challenge and concerns brought by 2019-nCoV to our healthcare workers. Front-line healthcare workers can become infected in the management of patients with COVID-19; the high viral load in the atmosphere, and infected medical equipment are sources for the spread of SARS-CoV-2. If prevention and control measures are not in place, these healthcare workers are at great risk of infection and become the inadvertent carriers to patients who are in hospital for other diseases. Nowadays a question that has not yet been clarified by science has been arises: is hydroxychloroquine associated with zinc compared to ivermectin associated with zinc effective as a prophylaxis for asymptomatic professionals involved in the treatment of suspected or confirmed case of COVID-19?
Detailed description
The study is a open-blind, randomised trial that will be conducted in asymptomatic professionals working in areas of high exposure and high risk of transmission of SARS-COV-2. After obtaining fully informed consent, the investigator will recruit workers in areas of high exposure and high risk of transmission of SARS-COV-2. Participants will be divided into 2 groups: * Hydroxychloroquine (HCQ) = 400mg twice on day 1, 400mg/day on day 2, 3, 4, and 5 followed by 400mg once every 05 days, for the next 7 weeks associated with 20 milligrams twice on day of active zinc for 45 consecutive days; * Ivermectin (IVM) = Dosage guidelines based on participant body weight, once on day for 2 consecutive days, This dose schedule should be repeated every 14 days for 45 days associated with 20 milligrams twice on day of active zinc.
Interventions
DRUGHydroxychloroquine
Oral hydroxychloroquine 400 mg twice a day on day 1, one 400 mg tablet on day 2, 3, 4, and 5, followed by one 400 mg tablets every 05 days until day 50th associated with 66 mg of zinc sulfate.
DRUGIvermectin
Oral ivermectin dosage guidelines based on participant body weight, once on day for 2 consecutive days. This dose schedule should be repeated every 14 days for 45 days associated with 20 milligrams twice on day of active zinc.
Sponsors
Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
The study is a open-blind, randomised trial.
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Aged 18 - 70 years; * Professionals working in areas of high exposure and high risk of transmission of SARS-COV-2; * Understands and agrees to comply with planned study procedures; * Signed informed consent for participation in the study.
Exclusion criteria
* Pregnancy or breastfeeding; * Major allergy to Hidroxychloroquine, chloroquine or 4-aminoquinolines; * Serum potassium lower than 3.4 mEq/l; * Serum magnesium lower than 1.7 mg/dL; * QTc interval \> 470 ms for man and \> 480 ms for woman; * Weight \< 40 kg;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of participants in whom there was a positivity for SARS-CoV-2. | Post-intervention at day 52 | Proportion of participants in whom there was a a positivity for SARS-CoV-2 through specific examination (RT-PCR) or by serology for antibodies specific (IgM and IgG), corroborated or not with clinical finding of COVID-19, defined as the occurrence of signs and symptoms suggestive of this disease. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of the QT interval. | Baseline, 3, 15 and 45 days post-intervention. | Measurement of the QT interval through electrocardiogram evaluation. |
| Widening of the corrected QT interval or with changes in heart rate on the ECG. | Day 52. | Proportion of participants who evolved with widening of the corrected QT interval or with changes in heart rate on the ECG. |
| Comparison of hematological and biochemical parameters. | Day 52. | Comparison of baseline (visit 0) and final (visit 5) values of hematological and biochemical parameters. |
| Occurrence of adverse events. | Post-intervention at day 52. | Proportion of occurrence of adverse events reported by participants or verified by the attending physician, or even observed in laboratory tests. |
| Participants who developed mild, moderate, or severe forms of COVID-19. | Post-intervention at day 52. | Proportion of participants who developed mild, moderate, or severe forms of COVID-19. |
| Proportion of participants who discontinue study intervention. | Post-intervention at day 52. | Proportion of participants who discontinue study intervention, |
| Proportion of participants who required hospital care. | Post-intervention at day 52. | Proportion of participants who required hospital care. |
| Proportion of participants who required mechanical ventilation. | Post-intervention at day 52. | Proportion of participants who required mechanical ventilation. |
| Assessment of COVID-19 symptom severity. | Post-intervention at day 52. | Severity of symptoms of COVID-19 measured by a visual analog scale (VAS), with scores ranging from zero to 10, where zero represents the absence of the symptom and 10 corresponds to the most intense manifestation of symptoms (severe dyspnoea). |
Countries
Brazil
Contacts
Primary ContactElisabete A Moraes, Professor
Outcome results
None listed